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OBJECTIVES We prospectively examined whether surgical treatment of secundum atrial septal defects
(ASDs) in patients 40 years old improves their long-term clinical outcome.
BACKGROUND Surgical treatment of secundum ASDs in adults 40 years old is a subject of controversy
because of the perception of good long-term clinical outcomes in patients with unrepaired
ASDs and the lack of data from randomized trials.
METHODS We recruited 521 patients 40 years old with secundum ASDs referred for treatment; 48
were excluded. Patients were randomly assigned to surgical closure (n  232) or medical
treatment (n  241). The primary and secondary end points were a composite of major
cardiovascular events (death, pulmonary embolism, major arrhythmic event, embolic cere-
brovascular event, recurrent pulmonary infection, functional class deterioration or heart
failure) and overall mortality, respectively. We assessed possible prognostic markers. The
analysis was performed on an intention-to-treat basis.
RESULTS The median follow-up period was 7.3 years (range 2 to 13). The risk of having the primary
end point was significantly higher in the medical group, which had a univariate hazards ratio
of 1.99 (95% confidence interval [CI] 1.23 to 3.22) and a multivariate hazards ratio of 1.85
(95% CI 1.08 to 3.17). Although the survival analysis did not reveal differences in overall
mortality between the surgical and medical treatments (hazards ratio 1.71, 95% CI 0.76 to
3.86), the multivariate analysis, adjusted by age at entry, mean pulmonary artery pressure and
cardiac index, demonstrated significant differences between the study groups (hazards ratio
4.09, 95% CI 1.41 to 11.89).
CONCLUSIONS Surgical closure was superior to medical treatment in improving both the composite of major
cardiovascular events and overall mortality in patients 40 years old with secundum ASDs.
This superiority was related to the mean pulmonary artery pressure, age at diagnosis and
cardiac index. Because of the higher risk of morbidity and mortality, we believe that anatomic
closure should always be attempted as the initial treatment for ASDs in adults 40 years old
with pulmonary artery systolic pressure 70 mm Hg and a pulmonary/systemic output ratio
1.7. The operation must be performed as soon as possible, even if the symptoms or the
hemodynamic impact seems to be minimal. (J Am Coll Cardiol 2001;38:2035–42) © 2001
by the American College of Cardiology
Surgical treatment of atrial septal defects (ASDs) is the
most common cardiac surgery performed for congenital
heart disease in adults; however, the long-term survival of
patients operated on after age 40 years remains controversial
(1–7). Comparisons between medical and surgical manage-
ment in adults have been based on retrospective data
(4,5,8,9). Lamentably, the presence of several biases in these
series is a common finding. Life expectancy may be short-
ened in some patients, but still long in others, regardless of
surgical treatment. Therefore, the excellent outcome re-
ported in some patients included in the surgical groups
might not necessarily be surgery-related. The identification
of strong predictive risk factors to select adult patients who
may benefit from anatomic closure remains to be demon-
strated. The aim of this open, prospective, randomized
clinical trial was to analyze the impact of surgical treatment
on long-term clinical outcome, as well as to identify possible
predictive factors related to a good long-term prognosis
when surgical repair is performed.
METHODS
Study group. Between November 1985 and August 1998,
the National Institute of Cardiology of Mexico “Ignacio
Cha´vez” recruited 521 patients 40 years old, who were
referred for ASD treatment, from major national medical
centers; 48 patients were excluded. After obtaining written
informed consent and a medical history and reviewing the
most recent echocardiogram, the patients underwent right
heart catheterization. For the purposes of this study, inclu-
sion criteria were isolated ASD (only ostium secundum
[88.2%] or sinus venosus defect [11.8%]), age 40 years at
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diagnosis, pulmonary/systemic output (Qp/Qs) ratio 1.7
and pulmonary artery systolic pressure 70 mm Hg. Ex-
clusion criteria were a contraindication for cardiac surgery,
severe comorbid disease, previous cardiac surgery, complex
congenital cardiac malformation, rheumatic valve disease,
coronary artery disease at diagnosis, mitral or aortic regur-
gitation, left ventricular dysfunction and fixed pulmonary
vascular resistance. Patients were randomly assigned on a
1:1 basis to surgical treatment of the defect or to continued
medical surveillance. A randomization procedure was per-
formed within six months after the first cardiac catheteriza-
tion by an independent researcher who verified the eligibil-
ity criteria. For data analysis, we compared the outcomes for
both surgical and medical treatment groups according to the
intention-to-treat principle. The cross-over group com-
prised patients randomly assigned to receive medical therapy
who met any of the following criteria: onset of new
symptoms or worsening of existing symptoms at the discre-
tion of the primary physician, refusal of the patient to
continue in the medical therapy group and a new unsus-
pected comorbid disease; these patients were then scheduled
for surgery. To avoid a waiting-time bias, surgically treated
patients underwent anatomic closure within six months
after randomization.
Data collection. Because the overall follow-up period be-
gan on the date of right heart catheterization (time zero), all
clinical, demographic, radiographic, electrocardiographic,
echocardiographic and laboratory data were obtained from
the medical records within three months before cardiac
catheterization; otherwise, the studies were repeated. Data
were collected by two different researchers and compared
afterward. Another researcher performed a third review if
any discordance was detected. Discrepancies were solved by
consensus. Postoperative cardiovascular events were further
classified as early (30 days) or late (30 days). The
information was entered in a computer-designed format to
facilitate analysis by using the Statistical Package for the
Social Sciences (SPSS, version 8.0 for Windows) (10).
Follow-up and clinical decisions. All patients were ad-
vised to appear for clinical and echocardiographic follow-up
evaluations at six- or eight-month intervals, or as soon as
either new symptoms appeared or the previous clinical state
deteriorated. Although the echocardiographic study was
used as one of the main markers to evaluate the hemody-
namic impact of ASD during follow-up in the medical
group, the primary physician required complete clinical and
hemodynamic evaluations, including right and left catheter-
izations before deciding to submit a patient to surgery.
End points. The primary end point was a compound index
of major cardiovascular events (assessed as time to first
event) of cardiac-related death, heart failure, pulmonary or
systemic embolism, recurrent pulmonary infection, sus-
tained ventricular tachyarrhythmia and progression of pul-
monary hypertension (elevation 20% from baseline). Sec-
ondary end points were the median time of survival, overall
mortality and incidence of atrial fibrillation or flutter.
Statistical analysis. Based on parametric data analysis from
previous studies in adults (1–9), we estimated a mean
frequency of 37% of the compound index used as a primary
end point in adult patients without surgical intervention
after the age of 40 years at the end of five-year follow-up.
For the primary end point, we considered a 15% difference
between surgical and medical groups as clinically relevant.
With 416 patients (208 per group), the study was designed
to have a power 80% for a two-tailed test at a 5% level of
significance.
Continuous variables are expressed as the mean value 
SD. Comparisons between the two groups were conducted
by using the Student t test for normally distributed contin-
uous variables or the Mann-Whitney U test for those
variables without normal distribution. For comparisons
among three or more groups, analysis of variance, or its
equivalent nonparametric test, was used. The chi-square or
Fisher exact test was used for categorical variables. The
association between individual variables and the clinical
outcome was initially assessed by bivariate analysis. Survival
was estimated using the Kaplan-Meier method, and differ-
ences among groups were assessed by the log-rank test (11).
Seven demographic, clinical and hemodynamic variables
were assessed by Cox hazards regression to identify predic-
tors of death and to examine the adjusted independent effect
of the relative hazards associated with factors measurable at
clinical presentation, while controlling for possible con-
founding variables. The seven variables were age at entry,
cardiothoracic ratio (CTR), previous atrial arrhythmia,
mean pulmonary artery pressure (mPAP), Qp/Qs ratio,
cardiac index and treatment group. Significant continuous
variables were selected for categorical analysis, and cut-off
points were determined to define subgroups for maximal
comparison with the log-rank statistic. Cox proportional
hazards ratios were estimated for each categorical variable,
using the most favorable category as the reference. For
multivariable analysis, first we explored all variables in a
forced model, and second, the independent factors associ-
ated with reduced time to the end point in stepwise forward
Cox proportional hazards modeling (12,13). The validity of
the proportionality assumption was verified graphically.
Checks for possible interactions were explored. Statistical
significance was inferred at p  0.05.
Abbreviations and Acronyms
ASD  atrial septal defect
CI  confidence interval
CTR  cardiothoracic ratio
mPAP  mean pulmonary artery pressure
NYHA  New York Heart Association
Qp/Qs  pulmonary/systemic output ratio
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RESULTS
Forty-eight of the initial adult patients 40 years old with
an isolated ASD were excluded: 22 (46%) who refused to
enter the study (they underwent surgical or medical treat-
ment without randomization); 10 (21%) whose pulmonary
artery pressure was 70 mm Hg; and 16 (33%) whose
Qp/Qs ratio was 1.5. The remaining 473 patients were
randomly assigned to either surgical (n  232) or medical
(n  241) treatment after right heart catheterization. There
were 369 women and 104 men. All patients were followed
for a mean period of 7.1 years (range 2.0 to 16.3). Only 32
patients (6.7%) discontinued follow-up: 20 due to change of
residence and 12 for unknown reasons. The time before
being lost to follow-up was 6  3.2 years, and all were
censored. During the follow-up, 22 patients initially as-
signed to medical treatment were crossed over to surgical
treatment; however, they remained as part of the medical
group until they were scheduled for surgical treatment (Fig. 1).
Age at the first right heart catheterization was similar for
the surgical and medical groups. No clinical or statistical
differences were found in mean follow-up, echocardio-
graphic variables, incidence of arrhythmia and degree of
cardiomegaly between the age groups. The clinical, echo-
cardiographic and hemodynamic profiles of the study group
are outlined in Table 1. Although the age at presentation
was variable (range 40 to 69 years), age 60 years was not
exceptional, and the mean (SD) age at entry was similar in
both treatment groups. Furthermore, the major clinical
feature at presentation was age-related: palpitations, vertigo
and/or incidental murmur were the most common present-
ing features in patients 50 years old; whereas dyspnea,
palpitations, acute event of paroxysmal supraventricular
arrhythmia and syncope were most common in patients
50 years old.
Arrhythmia was found in 125 patients at entry. A total of
101 patients (21.3%) had atrial fibrillation or flutter and
received digoxin and long-term anticoagulant therapy. The
most commonly referred symptoms were dyspnea and pal-
pitations. During follow-up, 10 (2.1%) cerebrovascular em-
bolic events occurred: 4 in the medical group and 6 in the
surgical group; however, no fatal outcomes were observed.
The New York Heart Association (NYHA) functional
class was II or I at entry in all patients; 15 (6.2%) patients in
the medical group deteriorated to functional class III over a
mean period of 6.1  5.2 years. In contrast, overall NYHA
functional class improved from class II to I in 18 patients
(57%) in the surgical group. New-onset atrial fibrillation or
flutter during follow-up was detected in 18 patients (7.4%)
in the surgical group and in 21 patients (8.7%) in the
medical treatment group.
All patients showed some degree of cardiomegaly, but
extreme cardiomegaly (CTR 0.65) was uncommon. In
this manner, 49 patients (21.1%) in the surgical group
(mean age 52.3  9.9 years) versus 51 patients (21.1%) in
the medical group (mean age 59.7 10.1 years) had a CTR
0.65. Furthermore, mPAP and the severity of tricuspid
regurgitation were not associated with CTR. Tricuspid
regurgitation was detected in 55 patients: 25 (10.7%) in the
surgical group and 30 (12.4%) in the medical group.
Extreme regurgitation was rare, occurring in only 3 (12%) of
25 surgically treated patients and 3 (10%) of 30 of medically
treated patients. We did not find any relationship between
the degree of tricuspid regurgitation and the advent of atrial
fibrillation. Although tricuspid regurgitation and CTR were
partially related, their impact on the survival rate was not
significant (collinearity and interactions were explored).
According to the univariate analysis, the following risk
markers were associated with the primary end point: age at
presentation, medical treatment and mPAP 35 mm Hg.
These variables remained as strong risk markers after the
multivariate analysis (Table 2). Interestingly, the overall
occurrence of the primary end point during follow-up was
generally consistent across subsets, based on predefined
baseline characteristics. Refusal of the patient to continue in
the medical treatment group was the case in 22 patients.
In the whole study group, the median survival time
Figure 1. Trial profile.
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without a major cardiovascular event (primary end point)
was 13.7  0.2 years (95% confidence interval [CI] 12.9 to
14.9 years). Of the 473 patients included, 76 had a major
cardiovascular event at 15 years, with an estimated cumu-
lative overall event-free survival rate of 99% at 1 year, 89%
at 5 years, 79% at 10 years and 58% at 15 years of follow-up.
Significant differences for the primary end point were found
when the analysis was performed according to the type of
treatment and age at entry (Figs. 2A and 2B). The log-rank
statistic showed differences between the three groups of age
at entry in both the medical and surgical groups (Figs. 2C
and 2D).
There were 50 events (20.7%) in the medically treated
versus 26 events (11.1%) in the surgically treated patients
(hazard ratio 2.0 [95% CI 1.20 to 3.2], p  0.004). The
total number of heart failures, strokes and embolic events
did not differ significantly (Table 3). Using a forward
multivariate Cox regression model to identify the best
associated variables with the primary end point during
follow-up, we found that age at diagnosis, mPAP 35 mm
Hg and medical treatment were the main risk markers.
Although the overall mortality rate did not differ signif-
icantly in the surgical (5.8%) and medical (4.3%) groups
(hazard ratio 1.6 [95% CI 0.76 to 3.86]), sudden death was
more frequent in the medical than in the surgical group
(2.9% vs. 0.9%, respectively), with a hazard ratio of 4.0 (95%
CI 0.83 to 19.3; p  0.08). Interestingly, when multivariate
Cox regression analysis was adjusted by age at entry, mPAP
35 mm Hg, previous atrial fibrillation or flutter and
cardiac index3.5 l/m2, a significant difference in mortality
was found between the surgical and medical groups (Table 4).
DISCUSSION
Surgical repair is still the main therapy for ASDs. Thus, the
life expectancy of patients with unrepaired ASDs is gener-
ally thought to be shortened (2,4,14–17). However, this
conclusion is supported by the results of several retrospective
studies that have mainly included young adult patients
(16,18,19). The previous belief that only 50% of patients
with unrepaired ASDs survive beyond the age of 40 years
and10% reach the age of 60 years, has not been confirmed
in many other observational studies (5,8,20,21). Further-
more, although the surgical closure of ASDs is frequently
Table 1. Characteristics at Trial Entry in Predefined Strata and Subgroups
Treatment Groups
Variable
Total Group
(n 473)
Surgical
(n  232)
Medical
(n  241) p Value
Females 369 (78.0%) 183 (78.9%) 186 (77.1%) 0.680
Age at entry (yrs) 50.8  10.4 50.1  9.3 51.9  10.8 0.059
40–50 225 (47.6%) 118 (50.1%) 107 (44.4%) 0.114
51–60 137 (28.9%) 69 (29.7%) 68 (28.2%)
60 111 (23.5%) 45 (19.3%) 66 (27.4%)
Age at last examination (yr) 58.3  13.3 57.6  10.0 59.1  10.6 0.116
Follow-up (yrs) 7.1  3.7 7.5  3.5 6.7  3.7 0.023
Cardiomegaly
CTR 0.50–0.59 129 (27.3%) 60 (25.9%) 69 (28.6%) 0.991
CTR 0.60–0.69 244 (51.6%) 123 (53.0%) 121 (50.2%)
CTR 0.70–0.80 100 (21.1%) 49 (21.1%) 51 (21.2%)
Previous arrhythmias 125 (26.4%) 58 (25.0%) 67 (27.8%) 0.532
Atrial fibrillation or flutter 101 (21.3%) 45 (19.4%) 56 (23.2%)
SVT 24 (05.0%) 13 (05.6%) 11 (04.6%)
Echocardiographic profile
EF (%) 65.0  11.0 63.1  11.0 66.1  11.3 0.849
55 115 (24.3%) 73 (31.5%) 42 (17.4%) 0.016
55 358 (75.7%) 159 (68.5%) 199 (82.6%)
RVDD (mm) 40.6  6.4 40.8  6.2 40.4  6.7 0.480
LVDD (mm) 41.0  6.3 40.0  6.4 41.9  6.1 0.310
LVSD (mm) 28.7  5.4 28.5  5.7 28.9  5.2 0.410
Hemodynamic profile
mRAP (mm Hg) 5.3  3.4 5.3  3.4 5.3  3.3 0.981
mPAP (mm Hg) 30.5  12.6 28.7  11.9 32.2  13.0 0.171
Qp/Qs ratio 2.3  0.7 2.5  0.8 2.1  0.5 0.061
Sao2 (%) 89.1  6.1 89.9  5.0 88.3  6.8 0.156
CO (L/min) 5.7  2.2 5.9  2.4 5.5  2.0 0.186
RVEDP (mm Hg) 5.6  3.4 5.5  3.4 5.8  3.5 0.113
PVR (Wood’s unit) 3.4  1.8 3.3  1.8 3.5  1.8 0.176
Data are expressed as the mean value  SD or number of patients (%).
CO  cardiac output; CTR  cardiothoracic ratio; EF  ejection fraction; LVDD  left ventricular diastolic diameter;
LVSD  left ventricular diastolic diameter; mRAP  mean right atrial pressure; mPAP  mean pulmonary artery pressure;
PVR pulmonary vascular resistance; Qp/Qs systemic/pulmonary output ratio; RVDD right ventricular diastolic diameter;
RVEDP  right ventricular end-diastolic pressure; Sao2  arterial oxygen saturation; SVT  supraventricular tachyarrhythmia.
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performed in patients 40 years old, there is a lack of
controlled follow-up studies comparing the long-term out-
come between surgical and medical treatment (22). Selec-
tion bias is a common error of some observational studies
that have attempted to describe the long-term outcome of
congenital heart disease gone untreated or unrepaired.
Thus, the inclusion of a small number of patients of specific
age groups may lead to an unreal perception of the long-
term outcome and misleading conclusions. This feature has
been demonstrated in other congenital heart diseases
(23,24).
Murphy et al. (2) pointed out that patients who have an
operation after the age of 40 years are at increased risk of
postoperative cardiovascular complications, whereas chil-
dren and young adults have an excellent prognosis. Specific
studies directed at exploring the clinical impact of the
surgical treatment of ASDs in patients 40 years old have
been called into question because of the multiple discrep-
ancies found. These discrepancies are partly due to the
heterogeneity of the study groups. To reduce this limitation,
Konstantinides et al. (5) used multivariate analysis to assess
179 consecutive patients 40 years old at diagnosis of
isolated ASD. They found a significant decrease in overall
mortality after surgical repair of the defect, and the relative
risk of death during the follow-up period was 0.31. These
results are similar to those of other studies (25,26). In
contrast, in our study, we found that the surgical treatment
of ASDs in adult life does not significantly alter the
prognosis in terms of mortality, whereas the risk for major
cardiovascular complications was clearly elevated in this
group. Nevertheless, several considerations must be pointed
out. First, our study was designed to be prospective and
randomized. Second, the clinical, demographic and hemo-
dynamic profiles were defined to include patients 40 years
old diagnosed with pulmonary artery pressure70 mm Hg,
without severe comorbid factors and with an excellent
functional class (NYHA class II or I). Third, although
mortality was analyzed, the primary end point of this study
was a compound index of major cardiovascular events.
Our study reports a large series of adults with ASDs (n
473) assessed, during a mean period of 7.3 years, at a single
center. Of these, 232 patients were assigned to surgical
treatment. Early postoperative complications were observed
in 24 patients; 14 had perioperative bleeding complications;
6 had transient ischemic attacks; 3 had complex arrhythmic
events; 1 had implantation of a definitive pacemaker (in-
jured sinus node of a patient with sinus venosus ASD); 2
had mediastinitis; and 1 had a pulmonary embolic event.
Nevertheless, all patients showed full recovery and were
discharged without sequelae.
In contrast, the incidence of nonfatal cardiovascular
complications during the follow-up period was reduced by
surgical treatment of the defect. This finding was frequently
related to a decreased incidence of recurrent pneumonia
(hazard ratio 4.4 [95% CI 1.80 to 10.7]). Although recur-
rent pulmonary infections were seldom included in most
previous studies, in the present study, 4 (28.5%) of 14 deaths
in the medical treatment group were related to this compli-
cation.
During long-term follow-up, atrial fibrillation or flutter
developed in 8% of all patients, although no difference was
observed between the surgical and medical groups. How-
ever, the onset of this arrhythmia did, in fact, differ: in
patients with surgical repair, most arrhythmic events began
Table 2. Hazards Ratios for Primary End Point (Major Cardiovascular Events) in Predefined Strata and Subgroups
Patients
(n)
Events
(n)
Univariate Analysis Adjusted by Age Multivariate Analysis
HR 95% CI HR 95% Cl HR 95% CI HR 95% CI
Age at entry (years)
40–49 225 16 1.00 Reference — — 1.00 Reference
50–59 137 29 3.41 1.85–6.29 — — 4.07 2.16–7.73
60 111 31 5.92 3.19–11.0 — — 6.30 3.31–12.0
Treatment
Surgical 232 26 1.00 Reference 1.00 Reference 1.00 Reference
Medical 241 50 1.99 1.23–3.22 1.92 1.18–3.11 1.85 1.08–3.17
CTR
0.65 373 53 1.00 Reference 1.00 Reference 1.00 Reference
0.65 100 23 1.32 0.80–2.15 0.91 0.55–1.51 0.66 0.37–1.14
mPAP
35 mm Hg 322 34 1.00 Reference 1.00 Reference 1.00 Reference
35 mm Hg 151 42 2.62 1.66–4.14 2.35 1.48–3.73 2.74 1.67–4.48
Qp/Qs ratio
2.5 281 52 1.00 Reference 1.00 Reference 1.00 Reference
2.5 192 24 0.57 0.35–0.92 0.62 0.38–1.01 1.15 0.47–2.79
Cardiac index
3.5 l/m2 227 36 1.00 Reference 1.00 Reference 1.00 Reference
3.5 l/m2 246 40 1.02 0.64–1.61 1.04 0.65–1.64 1.11 0.69–1.79
Atrial fibrillation or flutter at entry
No 348 49 1.00 Reference 1.00 Reference 1.00 Reference
Yes 125 27 1.27 0.79–2.04 0.95 0.58–1.54 1.05 0.64–1.76
CI  confidence interval; HR  hazards ratio; other abbreviations as Table 1.
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within two years after the operation; however, in the
medical group, the mean onset of arrhythmia was seven
years. Interestingly, mPAP was higher among patients with
unrepaired ASDs who developed atrial fibrillation or flutter
during follow-up, as compared with those patients who had
surgical repair (39  5 mm Hg vs. 31  3 mm Hg, p 
0.05). These results are similar to those reported by Gat-
zoulis et al. (27). In contrast, the preoperative mPAP in the
surgical group was not associated with the risk of developing
arrhythmias in the long term. These results suggest that the
mechanism responsible for triggering atrial fibrillation or
flutter might be different. In addition, the onset of atrial
fibrillation or flutter was related to long-term mortality in
the medical group, but not in the surgical group. Finally,
Figure 2. Event-free probability for primary end point by type of treatment and age at entry.
Table 3. End Point Results
End Point
Medical Treatment
(n  241)
Surgical Treatment
(n  232)
Hazards Ratio
(95% CI)
p
Value
Primary
Totality of events 50 (20.7%) 26 (11.1%) 2.0 (1.20–3.20) 0.0046
Heart failure 9 (3.7%) 5 (2.1%) 1.6 (0.52–4.97) 0.3982
Pulmonary embolism 4 (1.6%) 5 (2.1%) 0.9 (0.20–3.20) 0.8266
Peripheral embolism 1 (0.4%) 3 (1.3%) 0.4 (0.04–3.68) 0.4056
Stroke 4 (1.6%) 6 (2.6%) 0.5 (0.13–2.15) 0.3727
Recurrent pneumonia 24 (10.0%) 6 (2.6%) 4.4 (1.80–10.7) 0.0012
Sudden death 7 (2.9%) 2 (0.9%) 4.0 (0.83–19.3) 0.0837
Secondary
Total mortality 14 (5.8%) 10 (4.3%) 1.6 (0.76–3.86) 0.1934
CI  confidence interval.
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embolic events were related to this arrhythmia in 63% of all
patients. Therefore, our observations are consistent with the
perception that repair of ASDs does not significantly reduce
the risk of arrhythmias, but its long-term clinical impact
may be different in each group.
In contrast to the distribution of age groups reported in
previous studies, 70% of our patients were 40 to 60 years old
at diagnosis. Konstantinides et al. (5) also included patients
55 years old, but most patients included in their surgical
group had an operation before the age of 55 years. This may
be considered as a selection bias, so that the real impact of
age may be masked. Nevertheless, we confirm that age is an
independent risk marker to develop major cardiovascular
complications, even when adjusted by the clinical, hemody-
namic and echocardiographic profile. Although we did not
find significant differences in mortality, sudden death was
more frequent in the medical group than in the surgical
group (7 vs. 2), with a hazard ratio of 4.0 (95% CI 0.83 to
19.3).
Severe deterioration of functional class as a first finding at
diagnosis is rare. In general, when a patient is in NYHA
functional class IV or III at diagnosis, there is a comorbid
factor, such as left ventricular failure or right ventricular
dysfunction secondary to pulmonary hypertension or other
early complications. For this reason, we did not include
patients in NYHA functional class IV or III, as we believe
they comprise a special subgroup that needs to be evaluated
separately, and it is not possible to extrapolate our results to
this group.
Conclusions. We conclude that surgical treatment of
ASDs was superior to medical treatment in improving both
the composite of major cardiovascular events and overall
mortality in patients 40 years old. Superiority was related
to the cardiac index, mPAP and age at diagnosis. Because of
the higher risk of morbidity and mortality, we believe that
anatomic closure should always be performed as the initial
treatment for ASD in adults 40 years old, with a Qp/Qs
ratio 1.7 and pulmonary artery systolic pressure 70 mm
Hg. The operation must be performed as soon as possible,
even when the symptoms and hemodynamic impact seem to
be minimal.
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